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 Cancer is one of the leading causes of death in the world. Although widely used, 
currently available cancer treatment modalities such as surgery, chemotherapy and radiation have 
limited effects in curing the disease and prolonging the life of late-stage cancer patients. A novel 
therapy, laser immunotherapy (LIT) has been developed for the treatment of late-stage metastatic 
cancers. LIT uses laser light to kill cancer cells and a non-toxic immunoadjuvant, glycated 
chitosan (GC) to stimulate the host immune system. It fights against residual tumor cells, as well 
as metastases at distant sites. LIT is a combination of photothermal therapy and immunotherapy. 
The current application of LIT is non-invasive, using light to penetrate surface skin tissue to treat 
underlying tumor cells. Modifications to the LIT treatment are necessary to effectively treat 
patients with pigmented skin and deep tumors. Thus, interstitial laser immunotherapy (ILIT), 
using an invasive laser irradiation approach, is proposed. The present study is designed to 
investigate the effectiveness of ILIT using an 805-nm laser. DMBA-4 metastatic mammary 
tumor cells line in Wistar Furth female rats was used. Irradiation of rat tumors was performed 
using an interstitial fiber with a cylindrical diffuser. The temperature distribution inside the target 
tumor tissue, an important factor affecting the outcome of ILIT, was monitored with a 
thermocouple by inserting needle probes into the tissue around the cylindrical diffuser during 
laser irradiation. To measure the three-dimensional temperature distribution in the target tissue, 
the proton resonance frequency (PRF) method was conducted using a 7.1-Tesla magnetic 
resonance imager. Our results showed that the temperature distribution in tissue depended on 
laser power and irradiation duration. The temperature inside the target tumor varied with the 
distance from the laser diffuser tip. Thermal damage to the tumor was examined using 
triphenyltetrazoium chloride (TTC) staining as well as hematoxolin and erosion (H&E) 
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staining. Animal survival as well as tumor size over time was monitored. Our results indicate 
that ILIT had a much greater thermal impact on target tumors with less surface damage than LIT. 
The survival study also indicates that ILIT has better potential for treating metastases and deep 
tumors, while having fewer side effects than LIT. 
  
Keywords: Laser immunotherapy, interstitial laser irradiation, immunoadjuvant, cancer 
treatment, thermal damage, proton resonance frequency, rat tumor, DMBA-4 cell line, 

















Cancer is the second leading cause of death in the world, after heart disease. According to 
the U.S. National Cancer Institute, ―Cancer is a term used for diseases in which abnormal cells 
divide without control and are able to invade other tissues‖. Cancer normally spreads to other 
parts of the body through blood and lymph node systems. Cancer cells differ from normal cells 
in many physiological conditions, such as cytoskeletal changes, cell adhesion/motility, nuclear 
changes, and enzyme production. Cancer cells often change their appearance and are 
disorganized abnormally [1-4]. 
 There are thousands of new cancer cases every year. The most common types of cancers 
are breast cancer, bladder cancer, lung cancer, colon cancer, blood cancer, prostate cancer, and 
melanoma. In 2010, the most common type of cancer reported was lung cancer with an incident 
of 222,000 new cases and 157,300 deaths. There were about 40,000 estimated deaths due to 
breast cancer alone [5-6]. 
Among all the cancers, metastasis poses the most severe challenge and it is the major 
cause of treatment failure of cancer patients. The most common treatment modalities for cancer 
are chemotherapy, radiotherapy, and surgery [7-9]. Chemotherapy is a treatment process that 
uses anti-cancer drugs, targeting fast splitting cells. In radiotherapy, the controlled dose of 
radiation is used to directly destroy tumor cells. In surgery, the infected parts are cut away by 
using a scalpel or laser. Unfortunately, the long-term survival rates with these treatment methods 
have been low on late-stage challenge to the physicians and researchers. 
Facing this challenge, Chen and co-workers developed a novel technique for treatment of 
late-stage metastatic cancer with a combination of photothermal interaction and immunological 
stimulation called laser immunotherapy (LIT) [14-16]. LIT is a treatment method which uses the 
4 
 
laser to irradiate target tumors. Laser light interacts with biological tissues in three different 
ways: photochemical, photothermal, and photomechanical. Photothermal interaction can be an 
effective way to destroy tumor cells due to the sensitivity of tumor tissues to temperature 
increase. As the temperature is increased, normal tissue surrounding the target tumors can also be 
damaged and such damages need to be minimized to reduce the side effects [17-28]. In addition, 
for the long-term effect, LIT also includes immunological stimulation in combination with 
photothermal interaction.  
LIT has shown to be a promising method of cancer treatment lately. LIT can be 
considered as an in situ autologous vaccine that, through local intervention, uses whole tumor 
cell as the sources of tumor antigens from each individual patient without ex vivo preparation or 
pre-selection of tumor antigens. LIT, thus represents a new and significantly improved approach 
using a new and highly potent non-toxic immunoadjuvant, glycated chitosan (GC). Furthermore, 
the use of laser irradiation also reduces the tumor burden in addition to the release of tumor 
antigens. 
Specifically, LIT uses a near-infrared laser light to generate heat (photothermal 
interaction) to kill the tumors at specific temperatures and liberate tumor antigens. The injected 
GC interacts with the liberated tumor antigens to induce an immune response against the cancer 
[29-34]. 
Chen and co-workers first proposed the treatment of metastatic tumor using LIT in 1997. 
Initially, LIT was employed for non-invasive treatment of subcutaneous tumors, using an in situ 
light-absorbing dye. Deeper tumor couldn’t be treated effectively, because the light absorption of 
the tissue between the skin and the targeted tumor prevented sufficient laser energy from 
reaching the tumor. To overcome the limitations of LIT, interstitial laser immunotherapy (ILIT) 
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is developed using an optical fiber with cylindrical diffuser for the treatment of deep tumors. 
This is an invasive method that delivers the light directly to the center of the tumor, thus 
avoiding the attenuation of light due to the intervening tissues between the skin and the tumor. 
The response of the tumor and its surrounding normal tissue to the laser-induced heat is 
crucial in the treatment of cancer. It has been known that temperature increase affects biological 
response. Since tumor cells are more sensitive to the change in temperature than normal cells, 
thermal interactions can be used for therapeutic purposes. Between the temperatures of 40 degree 
to 43 degree Celsius, the cytotoxicity effect takes place in tumor cells than normal cells. The 
vascular destruction is higher in tumor cells at elevated temperatures because tumor cells have 
low pH and insufficient presence of oxygen [35-47]. 
In this study, we treated metastatic mammary tumors in rats using ILIT. We evaluated 
thermal effects using a near-infrared laser with an active cylindrical tipped interstitial fiber. The 
temperature measurement of the tissue during ILIT treatment was employed using thermocouple 
and magnetic resonance therapy (MRI) techniques. The thermocouple provides temperature 
measurement at a specific point whereas MRI provides a three dimensional temperature 
distribution. Water proton resonance frequency (PRF) has been used for this purpose. The 3-D 
presentation of the temperature distribution provides a more comprehensive understanding of the 
treatment process [48-56]. 
In pre-clinical studies and preliminary clinical trials for late-stage, melanoma and breast 
cancer patients, LIT have shown promising outcomes [57-60]. Not only are primary tumors 
treated successfully, but untreated metastatic tumors at distant sites are eliminated. Prolonged 
patient survival has been observed in both melanoma and breast cancer patients. In this study, we 
investigate the overall survival and immune responses of ILIT treatment on rat tumors. 
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The experiments performed in this study could lay the foundation for future clinical 




























Laser stands for Light Amplification by Stimulated Emission of Radiation. A laser emits 
electromagnetic radiation of a monochromatic wave which is amplified as the photons are 
stimulated. Laser light energy is very concentrated, which is different than other lights produced 
by other mechanisms. 
 
2.1.1 Properties of Lasers 
 The laser light is monochromatic. In this study, we used a near-infrared laser light 
with a wavelength of 805 nm. 
 A laser emits photons. Photons are perfectly aligned with each other and travel at the 
same speed. 
 The photons of the laser light are released from a small opening with high intensity. 
Therefore, the laser light can be used to direct energy efficiently to the targeted 
tumor. 
 The near-infrared laser light is invisible to the naked eye. In this wavelength range, 
biological tissue is almost transparent. 
 
2.1.2 Diode Laser 
In this study we used a specific type of laser called diode laser. A diode laser is formed 
by doping a crystal wafer to n-type and p-type regions using impurities. These n and p regions 
make a p-n junction. The p-n junction is also referred to as the diode. Holes from the p-region 
and electrons from the n-region are injected into the depletion region due to the differences in 
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potential between p and n regions. Since the two opposite charges are in the same region, 
recombination occurs. In this case the electrons and the hole combine to produce photons, which 
are released with energy equal to the difference between the states of the hole and the electron. 
This process is referred to as the spontaneous emission of photons. The emission of photons is 
seen in the form of light. 
While this occurs, stimulated emission, electrons and holes go through a process called 
recombination. During this process, when electrons and holes are close to one another, a photon 
with energy equal to the recombination energy triggers the stimulated emission by 
recombination. Because of this another photon is created. This new photon will have the same 
properties as the first photon. The proton will travel in the same direction and will be in the same 
phase. This process repeats as long as there is availability of holes and electrons in p and n 
regions respectively. As more and more charge carriers (holes and electrons) are injected into the 
depletion region, more and more photons with the same properties are produced. Hence, the 
stimulated emission of photons can be seen in the form of light referred to as the laser light. 
Light from a diode laser is monochromatic, focused, and intense. 
The construction of the diode laser provides a waveguide, a path for the electromagnetic 
radiation. Since the waveguide is formed on the crystal wafer, the photons have to pass through a 
very narrow path. In a diode laser, the two ends of the crystal wafer are cut and made very 
smooth. As the photons pass through the waveguide, they are reflected from the ends of the 
crystal. Photons moving in the waveguide cause stimulated emission which produces additional 
photons. At the same time, there is some absorption of photons causing loss of the light. Laser 





Figure 2.1. An 805-nm diode laser. 
 
2.1.3 Optical Properties of Biological Tissue 
 When considering the interaction between laser light and biological tissue, different 
optical properties need to be considered. In the interstitial studies we are interested in the 
absorption and scattering of the laser light. The absorption and scattering properties depend on 
the wavelength of the light used. Since the laser light is emitted from an extended active tip, it 
can deliver light to a large area in tissue. The biological response of the tissue depends on this 
temperature change. The power and duration of the laser light determine the injury level of the 
tissue. The tissue is primarily comprised of water and blood. This plays an important role in the 
absorption and scattering of the laser light on the tissue. At 600 nm blood absorption is relatively 
low and at 1300 nm water absorption starts to increase. Therefore, the wavelength range between 
600 nm and 1300 nm is called the optical window for tissue. Specifically, an 805 nm diode laser 






Thermocouple is a temperature measuring device. The device outputs a voltage which is 
proportional to the temperature difference. A thermocouple circuit is formed by joining two 
dissimilar metals. A small current due to Seebeck effect is created across the junction. The 
current or electro motive force that causes the current is proportional to the temperature of the 
junction. This small potential generated at the junction, is usually in the millivolt range. The 
schematic of thermocouple is given in Figure 2.2. 
A thermocouple thermometer employs two junctions – hot junction and cold junction. 
The hot junction is connected to the source of interest which is usually at a higher temperature. 
The cold junction remains at a reference temperature. The electro motive force (EMF) generated 
is directly proportional to the temperature difference between two junctions. The EMF to 
temperature ratio in a standard thermocouple is found to be in the range of 1 to 70 microvolt per 
degree Celsius (µV/°C). The EMF voltage does not mean the voltage is generated at the 
junctions of two metals but it is the voltage generated along the portion of the length of the two 
dissimilar metals that is subjected to a temperature gradient.  Because both lengths of dissimilar 
metals experience the same temperature gradient, the end result is a measurement of the 
temperature at the thermocouple junction. A table has been established worldwide that shows 
temperature vs. millivolt output figures for the various accepted thermocouple combinations. The 
reference table is all based on a reference or cold junction of 32 °F, which is the freezing point of 





Figure 2.2. Mechanism of Thermocouple. 
 
2.3 Magnetic Resonance Imaging 
We used MRI for our study. The MRI technique uses a magnetic field to study the 
alignment of protons in the targeted tissue. The tissue is mainly made up of water and it has an 
abundance of hydrogen atoms. Each hydrogen atom has one proton and one electron. In tissue, 
the protons are randomly oriented, each spinning on its own axis. Even though the protons are 
charged, they don’t act like magnets because of their random orientation. Once the tissue of 
interest is placed in the MRI machine, a magnetic field is applied and the protons align parallel 
or opposite to the field lines. These protons are still spinning in their own axis. This movement 
of magnetic moment of protons is called precession. The angular frequency of the process is 
given by Larmor equation: 
= B.        (1) 
where is angular frequency,  is gyromagnetic ratio and B is magnitude of the magnetic field.  
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Then radio frequency (RF) signal is applied to the already magnetized tissue to excite the 
protons to the upper energy state. The protons precess in a perpendicular direction to the field 
line. The small magnetic field of each proton adds up to produce a net transverse magnetic field 
which is detected by the detector coils. The precessing transverse magnetic field produces a 
changing magnetic field that produces an EMF in detector coils. The strength of EMF depends 
on the strength of the transverse magnetic field and hence on the number of nuclei contributing 
to the signal. Once the RF signal is turned off, the protons in the excited state return to the low 
energy state, releasing energy. This emission of electromagnetic waves, by the protons, after the 
termination of the RF signal, provides valuable information of the target tissue. The normal 
tissue and the diseased tissue have different return rates (or relaxation times), thereby 
differentiating these two types of tissues. The 3-D imaging in MRI is accomplished by using a 
large set of interactions of one atom with the other and by using RF pulses and delays. 
 




2.3.1 Characteristics of Magnetic Resonance 
2.3.1.1 Spin 
The nuclear spin quantum number S designates the spin of the nucleus. If the number of 
protons and neutrons are equal in a given nuclei then S is zero. 
 
2.3.1.2 Spin Angular Momentum 
The angular momentum in a nucleus is quantized. It is also called the magnetic quantum 
number m. The magnitude and orientation of the angular momentum takes the value from –S to 
+S, giving rise to 2S+1 number of angular momentum states. The z component of the angular 
momentum vector is given by: 
Sz = mħ,        (2) 
where ħ is reduced Planck’s constant. Similarly, the z component of the magnetic moment is 
given as [61-64]: 
z Sz  mħ,                              `        (3)
where  is the gyromagnetic ratio of the proton. 
 
Spin Behavior in a Magnetic Field 
An atom may be neutral when there is no force acting on it. But when an atom or nucleus 
is placed in an external magnetic field, there is an interaction of this external magnet field with 
the magnetic moment of the nucleus. The energy of a magnetic moment μ under the influence of 
a magnetic field B0 is given by: 
E = x x y y z z,          (4) 
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where  is the magnetic moment of the proton. 
When the magnetic field B0 is acting along the z-axis, 
E = z B0,        (5) 
 or, 
E = mhB0,        (6) 
As long as the magnetic field B0 is not zero, there will be different energies for different 
spin states. The energy difference between these two states can be found by the following 
equation [68]: 
hB0,          (7) 
 
2.3.1.3 Magnetic Resonance by Nuclei 
For magnetic resonance by nuclei, the specific level of energy is found by the Larmor 
equation. The right choice of frequency for the RF signal is important for resonant absorption by 
nuclear spins. The energy is given by the equation: 
E = h   
where, h is the plank’s constant and  is the resonant RF which is equal to the frequency as 
defined by the Larmor equation in a constant magnetic field B0. This amount of energy creates 
photons which then will be detected by the nuclear magnetic resonance (NMR) [65-70]. 
 
  2.3.1.4. Relaxation 
 The term relaxation refers to the nucleus returning to the previous state of net 
magnetization. When this occurs, the energy difference is emitted in the form of electromagnetic 
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radiation, a RF signal called the NMR signal. There are two different mechanisms that define the 
relaxation. They are as follows: 
 The longitudinal or spin lattice relaxation time (T1) 
 The transverse or spin-spin relaxation time (T2) 
 
T1: 
When a spin makes a transition from the high energy state to low energy state, the 
nucleus tries to come to equilibrium by releasing RF energy into the surrounding lattice. In other 
words, it is the energy exchange between spin and the lattice. 
T1 is also referred to as the recovery time of z component of the nuclear spin 
magnetization, Mz, coming to equilibrium state as symbolized by  Mz,eq. In general, 
Mz(t) = Mz,eq  [Mz,eq  Mz(0)]e
 t/T1
,
     
(9) 
When the spin magnetization vector, M, is inclined to XY plane, then Mz (0) = 0. The new 
recovery would be then as follows: 
Mz(t) = Mz,eq (1 e 
t/T1
),            (10) 
 After one T1 is completed, the longitudinal magnetization returns to 63% of its final 
value. T1 is dependent on the NMR frequency and the external magnetic field Bo. 
 
T2: 
When spins are precessing together, sometimes they interact with each other causing a 
phase change. This is due to the fact that each spin has its own magnetic field and it interacts 
with other spins, getting some spins out of phase [71-75]. 
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T2 is referred to as the decay constant of the spin magnetization vector (M) when 
perpendicular to the magnetic field B0. The component of M is symbolized as Mxy. When at time 
zero, the x-y magnetization will decay to zero as defined by the equation: 
Mxy(t) = Mxy (0)(1 e 
t/T2
).      (11) 
After time T2, the transverse magnetization decays to 63% of original value. 
T2 is always shorter than T1. T2 is less dependent on the magnetic field strength as compared to 
T1. 
 
2.4   Laser Immunotherapy (LIT) 
LIT is a cancer therapy with the combination of photothermal interaction and 
immunological stimulation. It induces an anti-tumor immune response for the control of 
abnormal growth of cells in the treated tumors. In order to increase the absorption of laser light 
by tumor tissue, indocyanine green (ICG) solution is injected into the tumor before the laser 
irradiation. ICG has an absorption peak around 800 nm which matches with the wavelength 
(805nm) of the laser. Due to this increased absorption of the laser with ICG, most of the laser 
energy is concentrated in the tumor cell. Hence, this increases the temperature of the tumor tissue 
while keeping the surrounding tissue at a lower temperature to prevent the damage to the normal 
tissue. When the laser light is focused on the tumor cells for certain duration of time, thermal 







2.4.1 Photothermal Response by Biological Tissues 
Biological tissues are sensitive to temperature increase. Temperature increases tissue 




C in tumor cells, cellular cytotoxicity occurs. Above 
42.5
o





 C, the cell dies at twice the normal rate. Tumor cells have low oxygen content 
resulting in a low pH level meaning a more acidic environment. In acidic medium, the 
cytotoxicity effect of heat is more pronounced and can cause more damage. For this reason, the 
tumor cells are more sensitive to temperature increase compared to the normal cells. The growth 
of tumor cells can be controlled by a temperature increase accomplished by using laser 
irradiation. Heat alone is not sufficient to stop complete growth of tumor cells [76-79]. 
 
2.4.2   Immune Response 
Photothermal therapy not only kills the tumor cells, but also induces immune response. 
As the immune response induced by photothermal therapy is regulated by temperature change, 





C) can modulate antigen presenting cells (APC), T cells and natural killing 




C) can increase the immunogenicity of 
tumor cells. Above cytotoxic temperature (43
o
C), an antigen source is formed which induces an 
anti-tumor immune response [34]. The antigens so produced could be tumor associated antigens, 
thermally induced heat shock proteins (HSP), and a large amount of self antigens. Dendritic cells 




Once the tumor cells are killed, their debris might not be able to transfer or produce 
enough antigens thereby reducing the anti-tumor immune response. The need for external 
interventions for anti-tumor immune response can be answered by adding more cytokines to 
increase the number of DCs [80-81].  There are different cytokines available, which can be used 
for this purpose depending upon the nature of tumor cells. Granulocyte monocyte colony 
stimulating factor (GM-CSF), tyrosine kinase 3 ligand (Flt3L) could be used. Similarly, 
cytotoxic T-lymphocyte antigen 4 (CLTA-4) blocking antibodies and TLR9 ligand provides 
further anti-tumor immune response [82-86]. 
 
2.5   Interstitial Laser Immunotherapy (ILIT) 
In ILIT, the tumor cell is targeted directly by inserting laser fiber into the target tissue. 
The laser light is absorbed directly without the assistant of indocyanine green or other light-
absorbing dye. ILIT has several advantages over LIT. LIT uses ICG solution in the middle of the 
tissue but does not guarantee the uniform distribution of laser light over the tumor tissue. ILIT 
does not need the ICG solution as the laser fiber is inserted directly into the middle of the tissue. 
Due to the high absorption of laser light by ICG solution in LIT therapy technique, dark skin 
patients run the risk of severe skin damage, which in turn can also limit the absorption of laser 
light by the tumor below the surface tissue. A cylindrical diffuser tip is used in the ILIT 
technique to deliver the laser light into deeper tissue. The cylindrical diffuser tip spreads the laser 
light cylindrically to create a larger, more uniform photothermal damage zone inside the tumor. 
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3. Experiment Setups and Methods 
3.1 Introduction 
The experiment for the treatment of metastatic mammary tumors in rats was conducted 
using an 805-nm diode laser. Healthy Wistar Furth female rats were injected with DMBA-4 
mammary tumor cells. The tumors were then treated using laser irradiation at different powers. 
The significance of the laser treatment was determined based on the rat survival rates. Since 
temperature distribution was the most crucial factor for the treatment, the temperature mapping 
was carried out using (i) thermocouple for temperature measurement at strategic locations and 
(ii) MRI  for 3-D temperature mapping. 
The first experiments were conducted at the University of Oklahoma Health Science 
Center (OUHSC) for survival studies and thermocouple temperature measurement purposes. 
Tumor-bearing rats were divided into different groups treated with different laser parameters to 
study their survival. A power meter was used to measure the laser power output. A fiber optic 
with a cylindrical diffuser was inserted into the tumor with the aid of needles. For the 
thermocouple temperature measurement, temperature probes were inserted into the tumor around 
the cylindrical diffuser fiber tip. Temperature at different distances from the cylindrical diffuser 
was measured. The treatment was followed by an intratumoral injection of GC. The histology of 
the tumor tissue was observed using triphenyltetrazoium chloride (TTC) staining. 
A second group of experiment was done at Oklahoma Medical Research Foundation 
(OMRF) for 3- D temperature measurement purpose. The magnetic field strength of the MRI 
device and the use of near infrared laser light were selected appropriately. The treatment 




3.2 Near Infrared Laser and Optical Fiber with Cylindrical Diffuser 
Near-infrared light was delivered using an 805-nm diode laser (Delta-30 
AngioDynamics, Queensbury, NY) with a maximum power output of 30 watts as shown in 
Figure 2.1. The laser light was delivered interstitially using a cylindrical diffuser fiber tip.  As 
shown in Figure 3.1, the diffuser fiber has a 1-cm active tip (Pioneer Optics, Bloomfield, CT). 
Output power was measured using a power meter (Ophir-Spricon, Logan, UT) as shown in 
Figure 3.2 before and after each tumor irradiation. 
 





Figure 3.2. A power meter. 
 
3.3 Preparation of Tumor for Interstitial Irradiation 
DMBA-4 metastatic mammary tumor cells (100,000 cells per rat) were injected into the 
upper back part of Wistar Furth female rats. Tumors were left to grow until the size of 1.0-1.5cm 
was reached, usually in approximately 7-10 days after tumor inoculation. These tumors were 
then irradiated by the laser using an optical fiber as shown in Figure 3.3. Laser irradiation was 
followed by 0.2 ml of immunoadjuvant GC. 
 
3.4 Experiment Setup for Survival Study 
A total of 91 rats were divided into 7 different groups, as shown in Table 3.1. The 




Figure 3.3. Irradiation of rat tumor with a cylindrical diffuser placed inside the tumor. 
 
Table 3.1 Rat Experiment Group 
Group # Treatment Number of Rats 
Group 1 Control 9 rats 
Group 2 1W/cm
2
 for 10 min 14 rats 
Group 3 1.5 W/ cm
2
 for 10 min 14 rats 
Group 4 2W/ cm
2
 for 10 min 14 rats 
Group 5 2.5 W/ cm
2
 for 10 min 14 rats 
Group 6 3W/ cm
2
 for 10 min 14 rats 
Group 7 2W/ cm
2






3.5 Experimental Setup for Thermocouple Measurements 
Two rats from each experimental group were selected for thermocouple measurement. 
For temperature measurement, each rat was allowed to lie on its stomach during irradiation. The 
thermocouple probes were positioned at a distance of 0.2 cm and 0.5 cm from the laser fiber tip. 
Before the experiments were performed, the thermocouple was calibrated on InstruNET 





as reference points. 
 
3.6 Experimental Setup for 3-D Temperature Determination 
Rats were treated with three different laser settings: (i) 1.6W for 10 min, (ii) 2.2W for 10 
min and (iii) 1.8W for 30 min. Incisions on the tumors were made using a 14-gauge needle. 
Laser light was delivered to the tumor by inserting the optical fiber with a 0.5 cm cylindrical 
active tip into the tumor guided by the pre-inserted 14 gauge needle. The rat was placed inside a 
commercially made acrylic tube. This tube was then placed inside MRI machine. Anesthesia was 
used on rats to acquire a constant breathing rate of 35 breaths per minute. 
 
3.6.1 PRF Calibrations and Validation  
Calibration on proton resonance frequency (PRF) method was done using chicken 
breast as a reference tissue. The chicken breast was cooled to 0
o
C overnight in an ice bath. 
Measurements using fiber optic sensors (FISO Technologies, Quebec, Canada, +/-0.5
o
C) 
were used as a reference. 
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Ex vivo bovine liver tissue was used to test our laser system and the PRF method. 
PRF was used to measure bovine liver tissue temperature profiles during 10-minute of laser 
irradiation with 1.5W using the 1-cm active cylindrical tip. 
 
3.7 MRI Method and Configuration 
In MRI method, the tissue temperature was determined using MRI phase measurement. 





where T is the change in temperature,  is the change in phase,  is the proton gyro-
magnetic ratio,  is the thermal coefficient, and TE is the echo time. 
The MRI experiment was accomplished with a 7.1-T MR imaging system (Para Vision 
5.0 Software, Bruker BioSpin MRI GmbH, and Germany) as shown in Figure 2.3. A fast low 
angle shot (FLASH) gradient-echo (GE) pulse sequence was used. The value of the echo time 
(TE) was 4 ms and that of the repetition time (TR) was 200 milli second. The scans were gated in 
this case so as to avoid the artifacts caused by motion due to respiration. Hence temporal 
resolution was calculated by taking the average of total elapsed time over the total number of 
cycles. 
For the MRI settings on the rats, ten slices (1 mm thickness) were selected along the 0.5 
cm length of the active cylindrical tip. Spatial resolution was set to 128X128 pixels whereas 
FOV (field of view) for 50X50 mm. With all these settings, it was estimated that an MRI 
machine would run at least 20-35 cycles to achieve the desired resolution. This took 
approximately 20-40 min. As described in section 3.6, the tumor was irradiated for two different 
25 
 
durations: two groups for 10 minute and one for 30 minute. In each of these three experiments, 
the tumor samples were imaged for 5 min before laser irradiation began and 5 min after laser 
irradiation ended. 
Similar procedures were followed for the bovine liver experiment with some minor 
changes. Nineteen slices (1 mm thickness) were used along the 1 cm length of active cylindrical 
tip. The field of view (FOV) setting was changed to 60X23 mm. 
 
3.7.1 Image Processing 
Using the real (Ren) and imaginary (Imn) parts of the raw MRI data, the phase 
difference ( between the phase at frame number n ( n) and the initial phase  at a 








n ArcTan .    
  (13) 
Afterwards, the temperature elevation was obtained from the phase-temperature 
relation using equation (12). Temperature maps were obtained using MatLab 2008 version 
7.6 (The Math Works Inc, Boston, MA). 
 
3.8 Observation of Tissue Damage Using Triphenyltetrazoium Chloride 
(TTC) Tissue Staining and Histology 
To assess tumor tissue viability after interstitial laser irradiation, TTC staining was used. 
TTC uses dehydrogenises enzyme and cofactor based reaction that converts the tetrazolium salt 
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to Formosan pigment within viable tissues, which turn the viable tissue from colorless to red-
maroon color. Thermal necrotic tissues lack intact enzymatic activities to metabolize the 
tetrazolium salt therefore do not stain and remain their native color. 
Rat tumor without laser treatment was used as control. Three hours after the treatment, 
the entire tumor with overlying skin was collected. The samples were then sliced under room 
temperature while remaining wet. The collected tissue samples were immersed into the TTC 
solution for an hour and then the TTC staining of the tumor was observed. Photographs were 







4.1 MRI Temperature Measurements 
4.1.1 Calibration of PRF with Chicken Breast Tissue 
Calibration of PRF was performed with the standard value obtained from the optical fiber 
sensors (FISO Technologies, Quebec, Canada, +/-0.5C). At first the laser irradiation was done on 
the chicken tissue at few specific locations. Temperatures of these locations were obtained 
directly from the sensors. Then the temperatures of the same locations were found by using the 
image obtained from PRF and applying equation 9. The readings from optical fiber sensors and 
PRF were consistent for the first 20 min as shown in Figure 4.1 
 
Figure 4.1. Internal temperature of chicken breast tissue measured during calibration. 
Temperature measured using PRF matches with that of the optical sensors for the first 20 































4.1.2 Temperature Profile of Bovine Liver Tissue during Laser Irradiation 
Nineteen 1-mm slices of bovine liver were partitioned along the 1 cm active cylindrical 




 slice. The 
maximum elevation of temperature was 35 degree Celsius. 
 
(a) (b)   (c) 
 
                                                         (d) 
Figure 4.2. Temperature distribution of cross-sectional liver tissue. From left to right: a) 
The 9th slice (at the middle of the active tip), b) the 8 th slice, and c) the 7th slice (close to the 
end of the active tip). d) A 3-D view of the temperature distribution of the 8 th slice. The 
liver was irradiated with a power of 1.5 watts for 10 minutes.  
 
The overall temporal profiles for temperature distribution at different positions with 
respect to diffuser tip are shown in Figure 4.2. The temperature 10 mm away from the diffuser 
tip is relatively low in comparison to that of other locations. 
A gradual temperature distribution can be seen in Figure 4.4 along the horizontal and 





Figure 4.3. Temperature distribution in liver tissue at different distances with respect to the active 
tip during interstitial laser irradiation. The liver tissue was irradiated with a laser power of 1.5 watts 




Figure 4.4. Temperature inside a liver tissue along the horizontal (a) and vertical (b) 




4.1.3 Temperature Profile of Rat Tumor 
As described earlier, three different time lengths and power of laser irradiation were used 
for the treatment of rat tumor. The 3-D image was captured by MRI. Figure 4.5 shows the image 
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of a rat tumor before and after the laser irradiation of 1.65W for 10 min. The different color 
represents different temperatures. 
 
                             (a)                                                                            (b) 
Figure 4.5. MRI images of a rat tumor during interstitial laser treatment with a power of 1.65W. 
The figures depict the images before a) and after b) 10 minutes of laser irradiation. 
 
Figure 4.6 shows the change in temperature inside of a tumor with respect to time at 1 
mm distance from the active tip irradiated with 1.65 W for 10 min. The temperature increase was 
18
o
C compared to the initial temperature. The error around 10-15 min could be due to the motion 
artifact. 
Figure 4.7 shows the change in temperature inside a tumor against time at a distance of 1 
mm and 3 mm from the active diffuser tip when  irradiated with 1.8 W for 30 min. At a distance 





Figure 4.6. Temperature inside a tumor 1 mm away from the active tip as function of 
time. A temperature spike around 13 minutes is likely due to the motion artifact. 
 
 
Figure 4.7. Temperature inside a tumor as function of time at the positions of 1 mm and 
3 mm away from the active tip. The laser power is 1.8 watts. A large temperature 
difference was observed between the locations 2 mm apart at this power. 
Comparing the temperature changes at time intervals of 10 min, 20 min and 30 min for 
both of these distances; we found the temperature changes to be 30 C, 45 C and 60 C for 1mm 
and 5 C, 15 C and 25 C for 3mm, respectively. 
32 
 
Figure 4.8 shows the temperature along two different axes on one slide after  laser 
irradiation of 1.8W. 
 
(a)         (b) 
Figure 4.8. Temperature inside a tumor along the vertical (a) and horizontal (b) axes      
of a selected slide after 10 min irradiation. Temperature drops sharply beyond 1mm.  The 
laser power is 1.8 watts. 
 
 Figure 4.9 shows the thermal images of a rat tumor at different time intervals- 0 min, 10 
min, 20 min and 30 min during a laser irradiation of 1.8W was used for 30 min. Laser irradiation 
caused high temperature increase with prolonged treatment. The region that was close to the 
fiber tip was very hot compared to the distant region. Hence, the temperature was found to be 
directly proportional to the time of laser irradiation whereas inversely proportional to the 





(a)                                (b)   (c)   (d) 
Figure 4.9. Thermal images of a tumor during laser treatment with 1.8 watts. The figures 





Figure 4.10. Thermal images of a tumor during laser treatment with 2.16W. The figures 
depict the images before (a) and after (b) 10-min laser irradiation. 
 
With laser irradiation power of 2.16 W for 10 min, the temperature elevation was 28
o
C 1 
mm distance from active diffuser tip. Figure 4.10 shows the thermal image of rat tumor 
before and after the laser irradiation. 
However, motion artifact contributed to noisy data beyond 2 mm, as shown in 






Figure 4.11. Temperature inside a tumor during laser treatment with 2.16W at different 
locations from the active tip of the cylindrical diffuser. The fluctuation of the data is due 




4.2   Rat Temperature Measurement using Thermocouple 
To compare the measurements using PRF with the thermocouple, we measured the 
temperature inside a rat tumor during laser irradiation. Thermocouple probes were placed 2 and 5 
mm away from the active tip. With 1 and 1.5 W of laser power and 30-min irradiation using 

















Figure 4.12. Temperature inside a tumor measured using thermocouple during laser 





































4.3   TTC Staining of Tissue Damage 
  The TTC staining of treated tumor samples showed a cylindrical thermal damage zone 
with a ring of thermal necrosis around the fiber and with decreased thermal tissue interruption in 
the regions further away from the fiber tip as shown in Figure 4.13. 
 
Figure 4.13. Tumor samples after interstitial laser irradiation. A cylindrical diffuser of 1-cm 
active length was placed in the center of the tumor. The tumor was irradiated with an output 
power of 1.5 watts for 10 minutes. The tumor sample was collected three hours after the 
laser irradiation. (A) Photo of a control tumor without treatment. (B) Photo of the control 
tumor in (A) after TTC staining. These control samples show uniform tissue structure (A) 
and uniform TTC staining (B), indicating a tumor sample with most viable tumor cells at the 
time of tissue collection. (C) Photo of a tumor after the interstitial irradiation.  (D) Photo of 
the tumor in (C) after TTC staining. The treated tumor sample clearly showed the thermal 









4.4   Rat Survival  
Figure 4.14 shows the combination of laser irradiation and immunostimulation resulted in 
the long-term survival of rats and prolonged survival time in treated groups. Particularly, the 
irradiations of 3 watts for 10 minutes and 2 watts for 30 minutes appear to be more effective than 
other laser parameters. The overall results in the Figure 4.14 show that interstitial laser 



















Days after Tumor Injection
Control
1 W, 10 Min
1.5 W, 10 Min
2 W, 10 Min
2.5 W, 10 Min
3 W, 10 Min
2 W, 30 Min
 





In this study, ILIT has been found to be an effective therapy method of treating metastatic 
cancer. ILIT uses the concept of efficient laser irradiation to kill the tumor cells with the process 
known as photothermal interaction. The efficiency of laser irradiation is increased by 
concentrating the laser light deeply and directly into the tissue tumor without irradiating the 
surface. In addition, the photothermal interaction is enhanced immunologically using GC. 
The laser light is delivered into the tumor tissue through a cylindrical tipped optical 
diffuser. Almost the entire laser energy is absorbed by the tumor cells. Whereas, when the laser 
light was irradiated on the surface, by the time it reached inside the tumor, much of the laser 
energy would have been lost to the intervening tissues between the skin and the tumor. 
Photothermal phenomenon is an exciting topic in research and in clinical applications. 
The photothermal-tissue interaction alone can cause direct tissue damage. With appropriate laser 
parameters, this interaction can be used in a variety of clinical applications such as lesion 
ablation, resurfacing, and tissue welding. The thermal damage can also be used to treat tumors. 
However, due to the absorption of the laser energy by tissue, the direct use of the laser limits the 
effective treatment area only to the surface tissue or to the region in close vicinity of the laser 
source. 
ILIT is an advanced form of LIT. In LIT therapy process, certain dyes were used so that 
most of the laser was absorbed by the target tissue. It turned out that even with dye enhancement 
the surface exposed to the laser light directly absorbed a large amount of laser energy. 
The results of ILIT depend on  temperature distribution and animal survival rates. 
Temperature distribution was one of the major concerns of ILIT, as we did not want to damage 
normal tissue. This part of study was focused on PRF temperature mapping with a known 
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measuring references. The calibration results using both PRF and optical sensors show the 
reliability of the temperature measurements. The homogeneous tissue composition in liver 
tissue allows for a smooth temperature gradient. In many cases, the temperature elevation 
decreases significantly at locations 1 mm or more away from the active t ip of the 
cylindrical diffuser.  
In our animal study, rats were divided into several groups and treated with different 
laser power for different durations. The survival rate of these different groups was studied. 
The groups that had the higher survival rate provided the clue as to which laser parameter 
could be the best as shown by the results in Figure 4.14. 
The balance of power and irradiation duration is crucial in ILIT. Raising the power 
may only increase temperature 5mm away by a small amount. We have seen from our 
results in Figure 4.7 and Figure 4.11 that higher power (>1W) and /or longer duration of 
irradiation constitute a relatively broader thermal damage zone (>8
o
C for a radius ≥3mm). 
For a typical tumor radius of ~5mm, 80-90% of the target area reached over 10
o
C increase 
following higher power (>2W) and longer time (30 min) as shown by the results in Figure 
4.7. 
However, the temperature increase is not the overriding criterion for laser 
immunotherapy since the tumor antigen release may require an appropriate temperature 
increase for the thermal damage to tumor tissue. 
While this current study focused on the thermal effects induced by interstitial laser 
irradiation, the biological effects induced by interstitial irradiation will be evaluated in the 
future, together with the application of the immunostimulant. 
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Variation in tissue composition not only affects the PRF results but also the 
temperature conductance. Abnormal temperature distribution is likely due to diversity in 
tissue composition including lipids, necrosis, and fluids. In these cases, a higher power or 
longer duration is needed to overcome these barriers. Nevertheless, moderate power and 
duration may be the best solutions in terms of biological and thermal interactions. 
The LIT method used earlier may not be optimal. Care must be taken when 
administering treatment to large tumors. It is worth noting that the beauty of ILIT is that it 
does not need to completely destroy all tumor cells in order to stimulate an effective 
immune response. 
Signal intensity and respiration stability are significant indicators of the quality and 
reliability of PRF measurements as shown by the results in Figure 4.6. Physical target size 
is also an important factor for imaging in terms of resolution. Due to a finite spatial 
resolution, the tumor size cannot be too small for a reliable assessment.  
Understanding how laser and tissue interact is one of the key factors to a better 
treatment outcome, particularly in laser immunotherapy, since an increase in temperature is 
crucial for tumor destruction and antigen release. We have shown in this study that ILIT 
can be an effective modality to induce desirable photothermal damage to tissue. We also 
demonstrated that together with application of immunoadjuvant, ILIT can be used to treat 
metastatic tumors. More importantly, this study demonstrated that the effectiveness of ILIT 
can be monitored by magnetic resonance imaging using PRF. Future studies will focus on 
improving our spatial and temporal resolutions. Furthermore, we will conduct more animal 
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